By Suherman Candra Maholtra 
The landscape of global vaccinology, dramatically reshaped by the rapid deployment of messenger RNA (mRNA) technologies during the COVID-19 pandemic, is witnessing a new evolution. While mRNA vaccines from manufacturers such as Pfizer-BioNTech and Moderna were credited with preventing an estimated 14.4 million deaths globally within their first year of use, they have also exposed significant logistical and biological hurdles. To address these limitations—ranging from strict cold-chain requirements to variable immune longevity—a multidisciplinary team from the Wyss Institute at Harvard University, the Dana-Farber Cancer Institute (DFCI), and several partner institutions has unveiled a sophisticated nanotechnology platform known as DoriVac.
This new platform utilizes "DNA origami," a method of folding DNA into precise three-dimensional shapes, to create a vaccine "chassis" that provides unprecedented control over how the immune system recognizes and responds to pathogens. Detailed in a recent publication in Nature Biomedical Engineering, the DoriVac system has demonstrated the ability to match the immune potency of current mRNA vaccines while offering superior stability, easier manufacturing, and the potential for broader protection against mutating viruses like SARS-CoV-2, HIV, and Ebola.
The mRNA Legacy: Successes and Emerging Challenges
The introduction of the first COVID-19 mRNA vaccine on December 8, 2020, marked a turning point in medical history. By utilizing lipid nanoparticles (LNPs) to deliver genetic instructions directly to human cells, these vaccines enabled the body to produce viral proteins and mount an immune defense in record time. However, as the pandemic progressed, several vulnerabilities in the mRNA-LNP framework became apparent.
The primary biological challenge lies in the waning of immune protection. Studies have shown that antibody levels generated by mRNA vaccines often peak and then decline significantly within six months, necessitating frequent booster shots. Furthermore, the rapid evolution of the SARS-CoV-2 virus has led to the emergence of variants like Omicron and its sub-lineages, which possess mutations that allow them to partially evade the immune defenses triggered by original vaccine formulations.
Logistically, mRNA vaccines are notoriously fragile. Because RNA is an inherently unstable molecule, it requires ultra-cold storage temperatures—often as low as -80 degrees Celsius—to prevent degradation. This "cold-chain" requirement creates massive barriers for vaccine distribution in developing nations and rural areas. Additionally, the process of packaging mRNA into lipid nanoparticles is complex and expensive, with manufacturers often struggling to achieve uniform "loading" of the genetic material across batches.
DNA Origami: A New Architectural Approach to Immunization
The DoriVac platform represents a fundamental shift in how vaccines are constructed. Unlike mRNA vaccines, which provide instructions for the body to build its own antigens, DoriVac uses DNA as a structural material to physically present both the antigen (the target protein) and the adjuvant (the immune stimulant) in a highly organized manner.
DNA origami involves the self-assembly of long single-stranded DNA "scaffold" molecules with the help of shorter "staple" strands. In the DoriVac system, these strands form a tiny, rigid square block. One side of this nanostructure is programmed to display adjuvant molecules—specifically CpG oligonucleotides—at precise nanometer distances. Research conducted by the Wyss Institute found that the spacing of these adjuvants is critical; when they are positioned exactly 3.5 to 7 nanometers apart, they more effectively trigger Toll-like receptor 9 (TLR9), a key sensor in the innate immune system.
The opposite side of the DNA structure is used to display the antigen. In their latest study, the researchers targeted the HR2 (heptad repeat 2) peptide region of the viral spike protein. This region is highly conserved, meaning it remains largely unchanged across different variants of a virus. By targeting HR2, the DoriVac vaccine aims to provide "broad-spectrum" protection that is less likely to be bypassed by new viral mutations.
Preclinical Validation: Mice and the Human Organ-on-a-Chip
To prove the efficacy of the DoriVac platform, the research team conducted a series of rigorous tests beginning with murine models. In mice, the DoriVac SARS-CoV-2 HR2 vaccine triggered a robust dual-pronged immune response. It stimulated humoral immunity, characterized by high levels of neutralizing antibodies, and cellular immunity, which involves the activation of T cells capable of destroying infected cells.
Recognizing that animal models do not always accurately predict human outcomes—a phenomenon that has led to the failure of many promising vaccines in clinical trials—the team utilized the Wyss Institute’s proprietary "Human Lymph Node-on-a-Chip" technology. This microfluidic device simulates the environment of a human lymph node in vitro, allowing researchers to observe how human immune cells interact with the vaccine in real-time.
In the human LN-on-a-Chip model, the DoriVac vaccine successfully activated human dendritic cells, which serve as the "sentinels" of the immune system. This activation led to a significant increase in the production of inflammatory cytokines and the proliferation of CD4+ and CD8+ T cells. These findings provided strong evidence that the platform could translate effectively to human patients.
A Head-to-Head Comparison with mRNA-LNP Standards
Perhaps the most significant aspect of the study was the direct comparison between DoriVac and existing mRNA-LNP vaccines, specifically those developed by Pfizer-BioNTech and Moderna. The researchers created a DoriVac variant that presented the full spike protein of SARS-CoV-2, mirroring the antigen used in the commercial mRNA shots.
The results showed that DoriVac produced a comparable level of immune activation to the mRNA vaccines in terms of T cell and B cell responses. However, the DNA-based platform exhibited several distinct advantages:
- Thermal Stability: DNA is significantly more stable than RNA. DoriVac vaccines do not require ultra-cold storage and can remain viable at standard refrigeration temperatures, or even room temperature, for extended periods.
- Manufacturing Precision: Because the DNA nanostructures self-assemble according to a programmed sequence, the composition of each vaccine dose is identical. This eliminates the "hit-or-miss" nature of lipid nanoparticle packaging.
- Safety Profile: Early data from DoriNano, the company spun off to commercialize the technology, suggests a promising safety profile with fewer off-target effects compared to the inflammatory potential of some lipid nanoparticle formulations.
Timeline of Development and Institutional Collaboration
The journey of DoriVac began long before the COVID-19 pandemic. Initially, the platform was conceived by William Shih, Ph.D., a Core Faculty member at the Wyss Institute and a Professor at Harvard Medical School and Dana-Farber Cancer Institute. Shih’s group had spent years pioneering DNA nanotechnology for use in cancer immunotherapy.
In early 2024, the team, led by Yang (Claire) Zeng, M.D., Ph.D., published findings showing that DoriVac could successfully treat tumors in mice by precisely delivering adjuvants to immune cells. When the pandemic hit, the team realized the "chassis" they had built for cancer could be adapted for infectious diseases.
The collaboration expanded to include Donald Ingber, M.D., Ph.D., the Founding Director of the Wyss Institute, whose expertise in AI-driven antiviral innovation and Organ-on-a-Chip systems helped refine the vaccine’s design. This cross-disciplinary approach—combining nanotechnology, immunology, and microfluidics—was essential for moving the platform from a theoretical concept to a viable vaccine candidate.
Global Health Implications and the Path Forward
The implications of a successful DNA origami vaccine platform are vast. For global health authorities, the ability to distribute vaccines without a complex cold chain could revolutionize pandemic preparedness in the Global South. The "last mile" of vaccine delivery, which has historically been the most difficult and expensive part of immunization programs, could be significantly simplified.
Furthermore, the versatility of the DoriVac chassis allows it to be rapidly "reprogrammed" for different pathogens. The researchers have already developed prototypes for HIV and Ebola, two viruses that have long eluded traditional vaccine strategies. By targeting conserved regions like HR2, DoriVac may offer a path toward a "universal" vaccine for various viral families.
"With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages," said William Shih. "Our study demonstrates DoriVac’s versatility and potential by taking a close look at the immune changes that are required to fight infectious viruses."
Donald Ingber added that the use of human LN-on-a-Chip technology has "dramatically raised the chances of success" for this new class of vaccines by providing a more accurate testbed than animal models alone.
As DoriNano moves toward clinical trials, the medical community will be watching closely. If the platform holds up in human subjects, it could signal the end of the mRNA-only era and the beginning of a new chapter in nanotechnology-driven medicine. The research was supported by a wide array of prestigious institutions, including the National Institutes of Health (NIH), the Bill and Melinda Gates Foundation, and the National Research Foundation of Korea, reflecting the global interest in finding more durable and accessible solutions to infectious disease.
